[Chen, Chen; Wei, Yu-hui] Lanzhou Univ, Dept Pharm, Hosp 1, Lanzhou 730000, Peoples R China.

[Ai, Qi-di] Hunan Univ Tradit Chinese Med, Changsha 410208, Peoples R China.

[Wei, YH ] L

Lanzhou Univ, Dept Pharm, Hosp 1, Lanzhou 730000, Peoples R China.

ABC transporter;antineoplastic agent;breast cancer resistance protein;chemokine;chemokine like factor 1;cisplatin;immunoglobulin enhancer binding protein;interleukin 1beta;kanglaite;multidrug resistance associated protein 2;multidrug resistance protein 1;tumor necrosis factor;unclassified drug;antineoplastic agent;carrier protein;chemokine;cisplatin;CKLF protein, human;herbaceous agent;immunoglobulin enhancer binding protein;kang-lai-te;MARVEL domain containing protein;antineoplastic activity;Article;cell invasion;cell migration;cell nucleus;cell viability;chemosensitivity;controlled study;drug potentiation;enzyme linked immunosorbent assay;gene overexpression;Hep-G2 cell line;human;human cell;immunofluorescence test;in vitro study;inflammation;liver cell carcinoma;MTT assay;protein expression;real time polymerase chain reaction;synergistic effect;transwell assay;tumor growth;tumor microenvironment;Western blotting;wound healing assay;cell survival;dose response;drug effect;drug potentiation;Hep-G2 cell line;liver cell carcinoma;liver tumor;metabolism;physiology;treatment outcome;Antineoplastic Agents;Antineoplastic Agents, Phytogenic;Carcinoma, Hepatocellular;Cell Survival;Chemokines;Cisplatin;Dose-Response Relationship, Drug;Drug Synergism;Drugs, Chinese Herbal;Hep G2 Cells;Humans;Liver Neoplasms;MARVEL Domain-Containing Proteins;Membrane Transport Proteins;NF-kappa B;Treatment Outcome